Michael Heffernan, R.Ph.

Michael Heffernan, R.Ph.

DirectoratCollegium Pharmaceutical· In proxies 2022–2025

Pay in FY2024Collegium Pharmaceutical stock -6.9% the same year

Michael Heffernan, R.Ph. was paid $466.5K in FY2024 (Dec). Collegium Pharmaceutical stock fell 6.9% that year.

Pay$100 in the stock at the end of FY21 → $153
Pay is from the Summary Compensation Table of each Collegium Pharmaceutical proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Collegium PharmaceuticalPublic company · 4 yr
    • Director2022 – Present · 4 yrStock in role +17%
  2. Biohaven Ltd.Public company
    • Director? – PresentNo stock prices for these years
  3. Synlogic, Inc.Public company
    • Director? – PresentNo stock prices for these years
  4. Trevi Therapeutics, Inc.Public company
    • Director? – PresentNo stock prices for these years

Roles come from the proxy statements of each company.

Activity

No new filings about this person in the feed.

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?